Abstract: Embodiments disclosed herein generally relate to wirelessly monitoring and controlling implantable magnetoelectric devices. Particularly, aspects of the present disclosure are directed to a system that includes an implantable device, a base station, and one or more sensors that are physically connected or wirelessly connected to the base station. The implantable device includes a magnetoelectric film, an electrical circuit coupled to the magnetoelectric film, and one or more electrodes. The base station includes a magnetic field generator and a magnetic transceiver.

Abstract: Embodiments disclosed herein generally relate to treatment evaluation and recommendation using implantable magnetoelectric devices. Particularly, aspects of the present disclosure are directed to a method that includes sending, to a user device of a subject, first software code that presents, at a user interface of the user device, requests for input that are informative of an instantaneous user characteristic of the subject. Second software code is sent to a base station that is coupled to implantable devices implanted in regions of the subject. The second software code causes the base station to send a signal to the implantable devices with an instruction to execute implant stimulation protocols. A communication that represents inputs detected at the user interface while or after the implant stimulation protocols were being executed is received. A treatment recommendation for the subject is determined based on the communication and is output.

Abstract: Embodiments disclosed herein generally relate to wirelessly monitoring and controlling implantable magnetoelectric devices. Particularly, aspects of the present disclosure are directed to a system that includes an implantable device, a base station, and one or more sensors that are physically connected or wirelessly connected to the base station. The implantable device includes a magnetoelectric film, an electrical circuit coupled to the magnetoelectric film, and one or more electrodes. The base station includes a magnetic field generator and a magnetic transceiver.

Abstract: This disclosure relates to medical implant systems and apparatuses capable of treating a seizure condition through the use of recording and stimulating electrodes. The apparatus includes an internal pulse generator in communication with a wireless communication module; one or more recording electrodes in communication with the internal pulse generator, wherein the one or more recording electrodes are configured to monitor to detect one or more field potentials produced by neural tissue in proximity to the one or more recording electrodes; one or more stimulating electrodes in communication with the internal pulse generator, wherein the one or more stimulating electrodes are configured to stimulate the vagus nerve.

Abstract: A method for assisting a user with meditation includes applying, to the user, a distributor at or near a brain portion of the user; operating a signal generator to provide a signal to the brain portion the user, the signal being applied to the brain portion of the user by the distributor; and engaging in one or more meditation practices by the user while the signal is being applied to the brain portion of the user. The signal may correspond to an electrical signal, and the distributor may include an anode and a cathode. The anode may provide the signal to the user, and the cathode may receive the signal from the user to transfer the signal back to the signal generator.

Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.

Abstract: An embolic coil conveying device and a preparation method thereof are disclosed. The embolic coil conveying device includes a pusher and an embolic coil. A distal end of the pusher and a proximal end of the embolic coil are connected to serve as a detachment section. A stretch-resistant thread is disposed in the embolic coil. The stretch-resistant thread is fixed at the proximal end of the embolic coil. A conductive wire is disposed in the pusher. The stretch-resistant thread is connected to the conductive wire. Compared with the prior art, the present invention has the advantages that the stretch-resistant thread is fixed at the proximal end of the embolic coil, so that the stretch-resistant thread is connected to the conductive wire, thereby reducing the length of the detachment section, making the detachment section more flexible, and avoiding kick-out of a microcatheter due to release of the embolic coil.

Abstract: A method for assisting a user with meditation includes applying, to the user, a distributor at or near a brain portion of the user; operating a signal generator to provide a signal to the brain portion the user, the signal being applied to the brain portion of the user by the distributor; and engaging in one or more meditation practices by the user while the signal is being applied to the brain portion of the user. The signal may correspond to an electrical signal, and the distributor may include an anode and a cathode. The anode may provide the signal to the user, and the cathode may receive the signal from the user to transfer the signal back to the signal generator.

Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.

Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.

Abstract: The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases.

Abstract: The invention provides multi-chamber encapsulated cell therapy cartridge devices that are capable of delivering biologically active molecules as well as methods of using these devices.

Abstract: The present invention provides a method of determining a treatment program for a subject. The method includes obtaining subject data representing the subject's condition. The subject data is used together with a model of the condition, to determine system values representing the condition. These system values are then used to determining one or more trajectories representing the progression of the condition in accordance with the model. From this, it is possible to determine a treatment program in accordance with the determined trajectories.

Abstract: The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.

Abstract: The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases.

Abstract: Described herein are shaped coil TMS electromagnets formed by two bent magnetic coil loops joined at a vertex having an angle between the outer coil regions of the coils that is typically less than 120 degrees (e.g., between about 45 and about 70 degrees, 60 degrees, etc.). The vertex region shaped to optimize the magnetic field projected from the TMS electromagnet. For example, the vertex region may be horizontal or vertical. In some variations the vertex region is formed by re-arranging the conductive windings forming the two coils so that they are no longer arranged in the same columnar structure that they are in the other portions of the bent magnetic coil loops. These TMS electromagnets may be well suited for use in deep-brain Transcranial Magnetic Stimulation.

Abstract: The present disclosure discloses an apparatus to be implanted in eyes, including: a configuration memory used for storing signal parameter configuration; a signal generator connected to the configuration memory and used for generating stimulating signals according to the signal parameter configuration in the configuration memory; electrodes connected to the signal generator and contact with outer surface of eye ball after implanted; a communication assembly connected to the configuration memory and used for receiving the signal parameter configuration, storing the received signal parameter configuration in the configuration memory; and a power supply connected to the configuration memory, signal generator and communication assembly, used for providing power. An update system for the apparatus is also disclosed.

Abstract: Described herein are Transcranial Magnetic Simulation (TMS) systems and methods of using them for emitting focused, or shaped, magnetic fields for TMS. In particular, described herein are arrays of TMS electromagnets comprising at least one primary (e.g., central) TMS electromagnet and a plurality of secondary (e.g., lateral or surrounding) TMS electromagnets. The secondary TMS electromagnets are arranged around the primary TMS electromagnet(s), and are typically configured to be synchronously fired with the primary TMS electromagnets. Secondary TMS electromagnets may be fired at a fraction of the power used to energize the primary TMS electromagnet to shape the resulting magnetic field. The secondary TMS electromagnets may be stimulated at opposite polarity to the primary TMS electromagnet(s). Focusing in this manner may prevent or reduce stimulation of adjacent non-target brain regions.

Abstract: Methods, devices and systems for Transcranial Magnetic Stimulation (TMS) are provided for synchronous, asynchronous, or independent triggering the firing multiple of electromagnets from either a single power source or multiple energy sources. These methods are particularly useful for stimulation of deep (e.g., sub-cortical) brain regions, or for stimulation of multiple brain regions, since controlled magnetic pulses reaching the deep target location may combine to form a patterned pulse train that activates the desired volume of target tissue. Furthermore, the methods, devices and systems described herein may be used to control the rate of firing of action potentials in one or more brain regions, such as slow or fast rate rTMS. For example, described herein are multiple electromagnetic stimulation sources, each of which are activated independently to create a cumulative effect at the intersections of the electromagnetic stimulation trajectories, typically by means of a computerized calculation.

Abstract: Cells and cell lines that are genetically modified to express the hCox-2 enzyme, which results in the upregulation of prostaglandin F2 alpha (PGF2a) on the cells have been obtained. Encapsulated cell therapy devices containing such cells or cell lines that are capable of delivering PGF2a, as well as methods of using these devices to deliver PGF2a to the eye and to treat ophthalmic disorders in patients suffering therefrom are also described.